GALILEO: Aflibercept provides marked improvement in visual acuity in results from follow-up to 76 weeks
Intravitreal injection of aflibercept provides marked improvement in visual acuity in treatment-naive eyes with macular edema secondary to central retinal vein occlusion in results from follow-up to 76 weeks in the phase III GALILEO study.
